Filing Details

Accession Number:
0001103021-20-000090
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-22 16:04:56
Reporting Period:
2020-05-21
Accepted Time:
2020-05-22 16:04:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1757833 James Vollins C/O Biodelivery Sciences Intl, Inc.
4131 Parklake Ave. Suite 225
Raleigh NC 27612
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-21 21,666 $3.90 21,666 No 4 M Direct
Common Stock Disposition 2020-05-21 21,666 $4.60 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2020-05-21 21,666 $3.90 21,666 $3.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
43,334 2030-01-30 No 4 M Direct
Footnotes
  1. On May 21, 2020, the Reporting Person sold an aggregate of 21,666 shares of the Issuer's Common Stock at a weighted average price of $4.60 per share. The highest sale price for the Common Stock was $4.62 per share and the lowest sale price was $4.57 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
  2. The stock options were issued to the Reporting Person on January 31, 2019, pursuant to a grant under the Company's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and one third vested on January 31, 2020. The remaining options will vest in equal portions on: (i) January 31, 2021; and (ii) January 31, 2022.